Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Pediatric nephrology (Berlin, West)

• Publication date

  2009-04-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00467-009-1176-zPMID 19347366
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt.

  2009cited by this paper
• Effect of Renin-Angiotensin-Aldosterone System Triple Blockade on Non-Diabetic Renal Disease: Addition of an Aldosterone Blocker, Spironolactone, to Combination Treatment with an Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker

  2008cited by this paper
• Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.

  2008cited by this paper
• Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.

  2008cited by this paper
• The aggravating mechanisms of aldosterone on kidney fibrosis.

  2008cited by this paper
• Relation of Dietary Salt and Aldosterone to Urinary Protein Excretion in Subjects With Resistant Hypertension

  2008cited by this paper
• Dietary salt regulates the phosphorylation of OSR1/SPAK kinases and the sodium chloride cotransporter through aldosterone.

  2008cited by this paper
• Rationale for Combination Angiotensin Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor Treatment and End-Organ Protection in Patients with Chronic Kidney Disease

  2007cited by this paper
• The incidence and implications of aldosterone breakthrough

  2007cited by this paper
• Systemic Hypertension and Proteinuria in Childhood Chronic Renal Parenchymal Disease

  2007cited by this paper
• Mechanisms of Disease: the role of aldosterone in kidney damage and clinical benefits of its blockade

  2007cited by this paper
• No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy--report from the ItalKid Project database.

  2007cited by this paper
• Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.

  2006cited by this paper
• Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample.

  2006cited by this paper
• Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function

  2006cited by this paper
• Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors.

  2006cited by this paper
• The effect of aldosterone blockade in patients with Alport syndrome

  2006cited by this paper
• Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.

  2006influential reference
• Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.

  2005cited by this paper
• Local Renal Aldosterone System and Its Regulation by Salt, Diabetes, and Angiotensin II Type 1 Receptor

  2005cited by this paper
• Clinical Experience with Spironolactone in Pediatrics

  2005cited by this paper
• Is aldosterone synthesized within the rat brain?

  2005cited by this paper
• Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.

  2005cited by this paper
• Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.

  2005cited by this paper
• Aldosterone Stimulates Collagen Gene Expression and Synthesis Via Activation of ERK1/2 in Rat Renal Fibroblasts

  2005cited by this paper
• Do human vascular endothelial cells produce aldosterone?

  2004cited by this paper
• Brain mineralocorticoid receptors: orchestrators of hypertension and end-organ disease

  2004cited by this paper
• Aldosterone escape during blockade of the renin–angiotensin–aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate

  2004cited by this paper
• Possible Contributions of Reactive Oxygen Species and Mitogen-Activated Protein Kinase to Renal Injury in Aldosterone/Salt-Induced Hypertensive Rats

  2004cited by this paper
• Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients.

  2004cited by this paper
• Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure.

  2004cited by this paper
• Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy

  2003cited by this paper
• Retarding progression of chronic renal disease: the neglected issue of residual proteinuria.

  2003cited by this paper
• Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.

  2003cited by this paper
• Safety of low-dose spironolactone administration in chronic haemodialysis patients.

  2003cited by this paper
• Epidemiology of chronic renal failure in children: data from the ItalKid project.

  2003cited by this paper
• Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy.

  2003cited by this paper
• Nongenomic vascular action of aldosterone in the glomerular microcirculation.

  2003cited by this paper
• Aldosterone Breakthrough During Angiotensin II Receptor Antagonist Therapy in Stroke-Prone Spontaneously Hypertensive Rats

  2002cited by this paper
• Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

  2001cited by this paper
• Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease.

  2001cited by this paper
• Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease.

  2001cited by this paper
• Role of dietary potassium in the hyperaldosteronism and hypertension of the remnant kidney model.

  2000cited by this paper
• Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.

  2000cited by this paper
• Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats.

  2000cited by this paper
• How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?

  1999cited by this paper
• Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

  1998cited by this paper
• Myocardial Production of Aldosterone and Corticosterone in the Rat

  1998cited by this paper
• Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).

  1998cited by this paper
• Role of the renin-angiotensin-aldosterone system in the progression of renal disease: a critical review.

  1997cited by this paper
• Recent progress in understanding aldosterone secretion.

  1997cited by this paper
• Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin.

  1996cited by this paper
• Role of aldosterone in the remnant kidney model in the rat.

  1996cited by this paper
• Chymase-dependent angiotensin II forming systems in humans.

  1996cited by this paper
• Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart.

  1995cited by this paper
• Aldosterone and cardiac fibrosis: in vitro studies.

  1994cited by this paper
• Distribution of mineralocorticoid and glucocorticoid receptor mRNA along the nephron.

  1993cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.

  1993cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

  1993cited by this paper
• Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level.

  1992cited by this paper
• Glomerular hypertrophy accelerates hypertensive glomerular injury in rats.

  1991cited by this paper
• Increase in plasma aldosterone during prolonged captopril treatment.

  1982cited by this paper
• Rise of plasma aldosterone during long-term captopril treatment.

  1981cited by this paper
• Letter: Dangers in nuclear-sexing the fetus.

  1974cited by this paper
• Secretion of a salt-retaining hormone by the mammalian adrenal cortex.

  1952cited by this paper
• Downloaded from http://hyper.ahajournals.org / by guest on February 21, 2013Role of Aldosterone in Renal Vascular Injury in Stroke-Prone Hypertensive Rats

  year unknowncited by this paper

• Hypertension in children with end-stage renal disease.

  2015cites this paper
• An update on the pathomechanisms and future therapies of Alport syndrome

  2013cites this paper
• Congenital Urinary Obstruction

  2012cites this paper
• Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative

  2012cites this paper
• [Aldosterone and kidney diseases: an emergent paradigm with important clinical implications].

  2011cites this paper
• Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease.

  2011cites this paper
• Management of Hypertension in the Young: Role of Antihypertensive Medications

  2011cites this paper